blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP1841781

EP1841781 - IL-22 FOR USE IN THE TREATMENT OF OBESITY, DIABETES, HYPERLIPIDEMIA, HYPERGLYCEMIA AND HYPERINSULINEMIA [Right-click to bookmark this link]
Former [2007/41]USE OF IL-22 FOR THE TREATMENT OF CONDITIONS OF METABOLIC DISORDERS
[2010/34]
StatusNo opposition filed within time limit
Status updated on  10.02.2012
Database last updated on 07.10.2024
Most recent event   Tooltip04.10.2013Lapse of the patent in a contracting state
New state(s): HU		published on 06.11.2013  [2013/45]
Applicant(s)For all designated states
Generon (Shanghai) Corp.
Suite 302/303, Building 9 1011 Ha Lei Road Z.J. Hi-Tech Park
Shanghai 201203 / CN
[2011/10]
Former [2008/16]For all designated states
Dhy & Co., Ltd.
Protcullis TrustNet Chambers
Road Town, Tortola / VG
Former [2007/41]For all designated states
Generon Corporation
7919 Paseo Aliso
Carlsbad, CA 92009 / US
Inventor(s)01 / HUANG, Yu, Liang
7919 Paseo Aliso
Carlsbad, CA 92009 / US
02 / CHEN, Xu, Wen
7919 Paseo Aliso
Carlsbad, CA 92009 / US
 [2007/41]
Representative(s)Chaillot, Geneviève, et al
Cabinet Chaillot
16-20 Avenue de l'Agent Sarre
B.P. 74
92703 Colombes Cedex / FR
[N/P]
Former [2010/17]Chaillot, Geneviève, et al
Cabinet Chaillot 16-20 Avenue de l'Agent Sarre B.P. 74
92703 Colombes Cedex / FR
Former [2007/41]Kern, Antonia
Schweiger & Partner Karlstrasse 35
80333 München / DE
Application number, filing date05784419.308.08.2005
[2007/41]
WO2005US28186
Priority number, dateCN200512310304.01.2005         Original published format: CN200510023103
[2007/41]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2006073508
Date:13.07.2006
Language:EN
[2006/28]
Type: A1 Application with search report 
No.:EP1841781
Date:10.10.2007
Language:EN
The application published by WIPO in one of the EPO official languages on 13.07.2006 takes the place of the publication of the European patent application.
[2007/41]
Type: B1 Patent specification 
No.:EP1841781
Date:06.04.2011
Language:EN
[2011/14]
Search report(s)International search report - published on:US13.07.2006
(Supplementary) European search report - dispatched on:EP17.03.2008
ClassificationIPC:C07K1/00, C07K14/54, A61K38/00, A61K38/20, A61P3/04, A61P3/06, A61P3/10
[2008/15]
CPC:
A61K38/20 (EP,US); A61K38/28 (EP,US); A61P3/00 (EP);
A61P3/04 (EP); A61P3/06 (EP); A61P3/08 (EP);
A61P3/10 (EP); A61P5/50 (EP); A61P9/00 (EP);
C07K14/54 (EP,US); A61K48/00 (EP,US) (-)
C-Set:
A61K38/20, A61K2300/00 (EP,US);
A61K38/28, A61K2300/00 (US,EP)
Former IPC [2007/41]C07K1/00, C07K14/54, A61K38/00, A61K38/20
Designated contracting statesAT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   NL,   PL,   PT,   RO,   SE,   SI,   SK,   TR [2007/41]
Extension statesALNot yet paid
BANot yet paid
HRNot yet paid
MKNot yet paid
YUNot yet paid
TitleGerman:IL-22 ZUR BEHANDLUNG VON FETTLEIBIGKEIT, DIABETES, HYPERLIPIDÄMIE, HYPERGLYKÄMIE UND INSULINRESISTENZ[2010/34]
English:IL-22 FOR USE IN THE TREATMENT OF OBESITY, DIABETES, HYPERLIPIDEMIA, HYPERGLYCEMIA AND HYPERINSULINEMIA[2010/34]
French:UTILISATION DE L'IL-22 POUR LE TRAITEMENT DE L'OBÉSITÉ, LA DIABÈTE, L'HYPERLIPÉMIE, L'HYPERGLYCÉMIE ET L'HYPERINSULINISME[2010/34]
Former [2007/41]VERWENDUNG VON IL-22 ZUR BEHANDLUNG VON STOFFWECHSELSTÖRUNGEN
Former [2007/41]USE OF IL-22 FOR THE TREATMENT OF CONDITIONS OF METABOLIC DISORDERS
Former [2007/41]UTILISATION DE L'IL-22 POUR LE TRAITEMENT DE TROUBLES METABOLIQUES
Entry into regional phase24.07.2007National basic fee paid 
24.07.2007Search fee paid 
24.07.2007Designation fee(s) paid 
24.07.2007Examination fee paid 
Examination procedure24.07.2007Examination requested  [2007/41]
03.07.2008Despatch of a communication from the examining division (Time limit: M04)
11.11.2008Reply to a communication from the examining division
31.03.2009Despatch of a communication from the examining division (Time limit: M04)
05.08.2009Reply to a communication from the examining division
05.02.2010Despatch of a communication from the examining division (Time limit: M02)
31.03.2010Reply to a communication from the examining division
22.09.2010Communication of intention to grant the patent
21.01.2011Fee for grant paid
21.01.2011Fee for publishing/printing paid
Opposition(s)10.01.2012No opposition filed within time limit [2012/11]
Fees paidRenewal fee
24.07.2007Renewal fee patent year 03
19.08.2008Renewal fee patent year 04
09.06.2009Renewal fee patent year 05
30.07.2010Renewal fee patent year 06
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipAT06.04.2011
BE06.04.2011
CY06.04.2011
CZ06.04.2011
DK06.04.2011
EE06.04.2011
FI06.04.2011
HU06.04.2011
LT06.04.2011
LV06.04.2011
PL06.04.2011
RO06.04.2011
SI06.04.2011
SK06.04.2011
BG06.07.2011
GR07.07.2011
ES17.07.2011
IS06.08.2011
IE08.08.2011
LU08.08.2011
PT08.08.2011
CH31.08.2011
LI31.08.2011
MC31.08.2011
[2013/45]
Former [2013/29]AT06.04.2011
BE06.04.2011
CY06.04.2011
CZ06.04.2011
DK06.04.2011
EE06.04.2011
FI06.04.2011
LT06.04.2011
LV06.04.2011
PL06.04.2011
RO06.04.2011
SI06.04.2011
SK06.04.2011
BG06.07.2011
GR07.07.2011
ES17.07.2011
IS06.08.2011
IE08.08.2011
LU08.08.2011
PT08.08.2011
CH31.08.2011
LI31.08.2011
MC31.08.2011
Former [2013/25]AT06.04.2011
BE06.04.2011
CY06.04.2011
CZ06.04.2011
DK06.04.2011
EE06.04.2011
FI06.04.2011
LT06.04.2011
LV06.04.2011
PL06.04.2011
RO06.04.2011
SI06.04.2011
SK06.04.2011
GR07.07.2011
ES17.07.2011
IS06.08.2011
IE08.08.2011
LU08.08.2011
PT08.08.2011
CH31.08.2011
LI31.08.2011
MC31.08.2011
Former [2012/35]AT06.04.2011
BE06.04.2011
CY06.04.2011
CZ06.04.2011
DK06.04.2011
EE06.04.2011
FI06.04.2011
LT06.04.2011
LV06.04.2011
PL06.04.2011
RO06.04.2011
SI06.04.2011
SK06.04.2011
GR07.07.2011
ES17.07.2011
IS06.08.2011
IE08.08.2011
PT08.08.2011
CH31.08.2011
LI31.08.2011
MC31.08.2011
Former [2012/20]AT06.04.2011
BE06.04.2011
CY06.04.2011
CZ06.04.2011
DK06.04.2011
EE06.04.2011
FI06.04.2011
LT06.04.2011
LV06.04.2011
PL06.04.2011
RO06.04.2011
SI06.04.2011
SK06.04.2011
GR07.07.2011
ES17.07.2011
IS06.08.2011
PT08.08.2011
CH31.08.2011
LI31.08.2011
MC31.08.2011
Former [2012/18]AT06.04.2011
BE06.04.2011
CY06.04.2011
CZ06.04.2011
DK06.04.2011
EE06.04.2011
FI06.04.2011
LT06.04.2011
LV06.04.2011
PL06.04.2011
RO06.04.2011
SI06.04.2011
SK06.04.2011
GR07.07.2011
ES17.07.2011
IS06.08.2011
PT08.08.2011
MC31.08.2011
Former [2012/11]AT06.04.2011
BE06.04.2011
CY06.04.2011
CZ06.04.2011
DK06.04.2011
EE06.04.2011
FI06.04.2011
LT06.04.2011
LV06.04.2011
PL06.04.2011
RO06.04.2011
SI06.04.2011
SK06.04.2011
GR07.07.2011
ES17.07.2011
IS06.08.2011
PT08.08.2011
Former [2012/10]AT06.04.2011
BE06.04.2011
CY06.04.2011
CZ06.04.2011
DK06.04.2011
EE06.04.2011
FI06.04.2011
LT06.04.2011
LV06.04.2011
RO06.04.2011
SI06.04.2011
SK06.04.2011
GR07.07.2011
ES17.07.2011
IS06.08.2011
PT08.08.2011
Former [2012/09]AT06.04.2011
BE06.04.2011
CY06.04.2011
CZ06.04.2011
EE06.04.2011
FI06.04.2011
LT06.04.2011
LV06.04.2011
SI06.04.2011
GR07.07.2011
ES17.07.2011
IS06.08.2011
PT08.08.2011
PL22.08.2011
Former [2012/01]AT06.04.2011
BE06.04.2011
CY06.04.2011
FI06.04.2011
LT06.04.2011
LV06.04.2011
SI06.04.2011
GR07.07.2011
ES17.07.2011
IS06.08.2011
PT08.08.2011
PL22.08.2011
Former [2011/52]AT06.04.2011
CY06.04.2011
FI06.04.2011
LT06.04.2011
LV06.04.2011
SI06.04.2011
GR07.07.2011
ES17.07.2011
IS06.08.2011
PT08.08.2011
PL22.08.2011
Former [2011/50]CY06.04.2011
FI06.04.2011
LT06.04.2011
LV06.04.2011
SI06.04.2011
GR07.07.2011
ES17.07.2011
IS06.08.2011
PT08.08.2011
PL22.08.2011
Former [2011/49]CY06.04.2011
FI06.04.2011
LT06.04.2011
SI06.04.2011
GR07.07.2011
ES17.07.2011
PT08.08.2011
Former [2011/47]LT06.04.2011
SI06.04.2011
PT08.08.2011
Former [2011/41]SI06.04.2011
Documents cited:Search[A]WO9408606  (SCHERING CORP [US], et al);
 [A]US2001023070  (EBNER REINHARD [US], et al) [A] 1-13 * page 51, line 12, paragraph 329 *;
 [AP]  - WOLK KERSTIN ET AL, "Interleukin-22: A novel T- and NK-cell derived cytokine that regulates the biology of tissue cells", CYTOKINE & GROWTH FACTOR REVIEWS, (200610), vol. 17, no. 5, ISSN 1359-6101, pages 367 - 380, XP002468851 [AP] * the whole document *

DOI:   http://dx.doi.org/10.1016/j.cytogfr.2006.09.001
International search[Y]US4849227  (CHO YOUNG W [US]);
 [X]US2001023070  (EBNER REINHARD [US], et al);
 [A]US2003235561  (VANDENBURGH HERMAN H [US], et al)
Examination   - XIE ET AL, "Interleukin (IL)-22, a novel human cytokine that signals through the interferon receptor-related proteins CRF2-4 and IL-22R", THE JOURNAL OF BIOLOGICAL CHEMISTRY, (20000629), vol. 275, no. 40, pages 31335 - 31339, XP002164307

DOI:   http://dx.doi.org/10.1074/jbc.M005304200
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.